[{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"CBP\/p300","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"CBP\/p300","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"CBP\/p300","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pathos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"||CBP\/p300","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pathos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pathos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Pathos \/ Inapplicable"},{"orgOrder":0,"company":"Pathos","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series D Financing","leadProduct":"Pocenbrodib","moa":"||CBP\/p300","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pathos","amount2":0.37,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.37,"dosageForm":"oral","sponsorNew":"Pathos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pathos \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Pocenbrodib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          American Thoracic Society
                          Not Confirmed
                          American Thoracic Society
                          Not Confirmed

                          Details : The proceeds will support advancement of the company’s clinical-stage pipeline, which includes FT-7051 (pocenbrodib) is being evaluated for metastatic castration-resistant prostate cancer.

                          Product Name : FT-7051

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 15, 2025

                          Lead Product(s) : Pocenbrodib,Abiraterone Acetate,Olaparib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : $365.0 million

                          Deal Type : Series D Financing

                          blank

                          02

                          American Thoracic Society
                          Not Confirmed
                          American Thoracic Society
                          Not Confirmed

                          Details : FT-7051 (pocenbrodib) is a CBP/p300 inhibitor, is being investigated as alone and in combination with abiraterone acetate, in patients with mCRPC.

                          Product Name : FT-7051

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 20, 2025

                          Lead Product(s) : Pocenbrodib,Abiraterone Acetate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          American Thoracic Society
                          Not Confirmed
                          American Thoracic Society
                          Not Confirmed

                          Details : FT-7051 is designed to attach to the CBP/p300 bromodomain potently and selectively, which then blocks androgen binding and reduces AR activation. In preclinical studies, FT-7501 demonstrated activity in both prostate cancer models that were sensitive.

                          Product Name : FT-7051

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 26, 2022

                          Lead Product(s) : Pocenbrodib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          American Thoracic Society
                          Not Confirmed
                          American Thoracic Society
                          Not Confirmed

                          Details : FT-7051 is designed to attach to the CBP/p300 bromodomain potently and selectively, which then blocks androgen binding and reduces AR activation.

                          Product Name : FT-7051

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 10, 2021

                          Lead Product(s) : Pocenbrodib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          American Thoracic Society
                          Not Confirmed
                          American Thoracic Society
                          Not Confirmed

                          Details : FT-7051 is a selective inhibitor of CREB-binding protein/E1A binding protein p300 (CBP/p300) and a co-activator of androgen receptor. Phase 1 study includes late-line patients and patients with AR-v7 splice variants for whom there are no approved therapi...

                          Product Name : FT-7051

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 20, 2021

                          Lead Product(s) : Pocenbrodib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank